Gregory Tobin

Dr. Gregory Tobin

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 1999 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JKJukka Kervinen
Jukka Kervinen
GTGregory Tobin
Gregory Tobin
JCJulia Costa
Julia Costa
DWDavid S. Waugh
David S. Waugh
AWAlexander Wlodawer
Alexander Wlodawer
AZAlexander Zdanov
Alexander Zdanov
We determined at 2.3 Å resolution the crystal structure of prophytepsin, a zymogen of a barley vacuolar aspartic proteinase. In addition to the classical pepsin‐like bilobal main body of phytepsin, we also traced most of the propeptide, as well as an independent plant‐specific domain, never before described in structural terms. The structure revealed that, in addition to the propeptide, 13 N‐terminal residues of the mature phytepsin are essential for inactivation of the enzyme. Comparison of the plant‐specific domain with NK‐lysin indicates that these two saposin‐like structures are closely related, suggesting that all saposins and saposin‐like domains share a common topology. Structural analysis of prophytepsin led to the identification of a putative membrane receptor‐binding site involved in Golgi‐mediated transport to vacuoles.

1 November 2008 in Vaccine
Verified
Journal Article
Closed access
GTGregory Tobin
Gregory Tobin
JTJessie D. Trujillo
Jessie D. Trujillo
RBRuth V. Bushnell
Ruth V. Bushnell
GLGeorge Lin
George Lin
ACA. Ray Chaudhuri
A. Ray Chaudhuri
PNPeter L. Nara
Peter L. Nara

1 June 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
OHO. M. Zack Howard
O. M. Zack Howard
ASAiko-Konno Shirakawa
Aiko-Konno Shirakawa
JTJim A. Turpin
Jim A. Turpin
AMAndrew Maynard
Andrew Maynard
GTGregory Tobin
Gregory Tobin
Michael DeanMichael Dean
Michael Dean
Analysis of CCR5 variants in human immunodeficiency virus, type 1 (HIV-1), high risk cohorts led to the identification of multiple single amino acid substitutions in the amino-terminal third of the HIV-1 co-receptor CCR5 suggesting the possibility of protective and permissive genotypes; unfortunately, the low frequency of these mutations did not led to correlation with function. Therefore, we used analytical methods to assess the functional and structural significance of six of these variant receptors in vitro. These studies showed three categories of effects on CCR5 function. 1) Mutations in the first extracellular domain of CCR5 severely reduce specific ligand binding and chemokine-induced chemotaxis. 2) An extracellular domain variant, A29S, when co-expressed with CD4, supported HIV-1 infection whereas the others do not. 3) The transmembrane region variants of CCR5 support monotropic HIV-1 infection that is blocked by addition of some receptor agonists. Mutations in the first and second transmembrane domains increase RANTES (regulated on activation normal T-cell expressed) binding affinity but did not affect MIP1β binding affinity presumably based on differences in ligand-receptor interaction sites. Furthermore, the CCR5 transmembrane mutants do not respond to RANTES with the classical bell-shaped chemotactic response curve, suggesting that they are resistant to RANTES-induced desensitization. These data demonstrate that single amino acid changes in the extracellular domains of CCR5 can have profound effects on both HIV-1 co-receptor and specific ligand-induced functions, whereas mutations in the transmembrane domain only affect the response to chemokine ligands.

1 November 1989 in Cell
Verified
Journal Article
Closed access
PDF file
GTGregory Tobin
Gregory Tobin
DYDorothy C. Young
Dorothy C. Young
JFJames B. Flanegan
James B. Flanegan

1 November 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SGStefanie Glathe
Stefanie Glathe
JKJukka Kervinen
Jukka Kervinen
MNManfred Nimtz
Manfred Nimtz
GLGrace H. Li
Grace H. Li
GTGregory Tobin
Gregory Tobin
JCJulia Costa
Julia Costa
The primary translation product of barley aspartic proteinase, phytepsin (EC 3.4.23.40), consists of a signal sequence, a propart, and mature enzyme forms. Here, we describe post-translational processing and activation of phytepsin during its transport to the vacuole in roots, as detected by using metabolic labeling and immunoprecipitation. After removal of the signal sequence, the glycosylated precursor of 53 kDa (P53) was produced and further processed to polypeptides of 31 and 15 kDa (P31 + P15) and, subsequently, to polypeptides of 26 and 9 kDa (P26 + P9), 45 min and 24 h after synthesis, respectively. The processing occurred in a late-Golgi compartment or post-Golgi compartment, because brefeldin A inhibited the processing, and P53 acquired partial endoglycosidase H resistance 30 min after synthesis, whereas P15 was completely resistant. The N-glycosylation inhibitor tunicamycin had no effect on transport, but the absence of glycans on P53 accelerated the proteolytic processing. Phytepsin was also expressed in baculovirus-infected insect cells. The recombinant prophytepsin underwent autoproteolytic activation in vitro and showed enzymatic properties similar to the enzyme purified from grains. However, a comparison of the in vitro/in vivoprocessing sites revealed slight differences, indicating that additional proteases are needed for the completion of the maturationin vivo.

9 April 1999 in Vaccine
Verified
Journal Article
Closed access
XFXavier Forns
Xavier Forns
SESuzanne U Emerson
Suzanne U Emerson
GTGregory Tobin
Gregory Tobin
IMIsa K Mushahwar
Isa K Mushahwar
RPRobert H Purcell
Robert H Purcell
JBJens Bukh
Jens Bukh